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ABSTRACT

CONSTRUCTION OF A COL11A1 TRANSGENE VECTOR

Cameron McKell Beck
Department of Physiology and Developmental Biology
Master of Science

Background: Cartilage disorders affect millions of people in the United States alone,
with effects ranging from poor skeletal development and joint pain to shortened
lifespan and perinatal lethality. Many of these disorders have their root in defects of
collagen, type XI collagen being among the most important. A mouse model of such a
type XI collagen defect is the chondrodysplasia (cho) mutant. Mice homozygous for
this null mutation in the Col11a1 gene do not express the α1 chain of type XI
collagen. This results in a functional knockout of type XI collagen, leading to
insufficient skeletal development and perinatal lethality. Objective: 1) To construct a
transgenic expression vector designed to express a human COL11A1 cDNA in a
cartilage-specific manner. This transgene will be used in future studies to correct the
type XI collagen defect in homozygous cho mice. 2) To place the cDNA in an in vitro
expression vector to be used for in vitro transcription/translation assays. Methods and

Results: Through the relatively new approach of “recombineering”, the coding
sequence of a human COL11A1 cDNA was constructed from two cloned cDNA
fragments. A copy of the cDNA was inserted into the pcDNA3.1 expression vector for
in vitro transcription/translation assays.
Another copy of the cDNA was fused with a genomic mouse α-globin
fragment to provide a polyadenylation signal. The resulting cDNA/α-globin segment
was inserted into p1757, the expression vector to be used for future transgenic studies.
p1757 contains a Col2a1 promoter, a β-globin splice sequence and a Col2a1 enhancer.
The cDNA/α-globin segment was inserted between the splice sequence and the
enhancer. With the cDNA in this expression cassette COL11A1 can be expressed in a
chondrocyte-specific manner in transgenic studies of the cho mouse model.
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Introduction

Importance of cartilage
Cartilage plays a fundamental role in skeletal development, as well as in other
structural settings including the lining of articular surfaces within many synovial
joints. For these reasons, hereditary and acquired defects in this important connective
tissue can have severe consequences on human development and health. Millions in
the United States alone suffer from disorders such as osteoarthritis, achondrogenesis,
and Stickler Syndrome, which have their root in insufficient, malformed, or damaged
cartilage1. Mutations in collagen type XI, an essential component of hyaline cartilage,
have been implicated in such disorders2.
Structure and function of type XI collagen
Type XI collagen, along with collagen type II, forms the collagen fibrils that
give hyaline cartilage its characteristic tensile strength and durability3. Though
collagen XI is a quantitatively minor component of these collagen fibrils, its unique
morphology allows it to perform an essential regulatory function in the fibril.
Like all collagens, type XI collagen is a trimeric molecule. The collagen XI
molecule is a heterotrimer comprised of three α polypeptide chains, α1, α2 and α3, the
products of three distinct genes, Col11a1, Col11a2, and Col2a1, respectively. As with
other fibril-forming collagens, type XI collagen is secreted from chondrocytes as a
procollagen containing several characteristic domains: an amino propeptide containing
a short triple helical segment, followed by an extended triple helical domain, and
terminating with a carboxy propeptide. While all fibrillar collagens undergo
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proteolytic processing in the extracellular matrix to produce the mature form of the
molecule, collagen XI is processed more slowly and incompletely, allowing it to retain
most of its N-terminal domain4. When incorporated into growing fibrils, this domain
of collagen XI is excluded from the interior of the fibril, where the majority of the
molecule is found5, 6. This globular domain, residing on the surface of the collagen
fibril, is thought to limit the diameter of growing fibrils, most likely by sterically
blocking the accumulation of additional collagen molecules past a certain fibril
diameter7. Fibrils without collagen XI, containing only type II collagen, become much
thicker and spindle-shaped without this regulation of collagen accretion8. The altered
shape and content of these fibrils appear to adversely affect their interaction with the
other components of the ECM and inhibit their ability to serve the structural functions
of normal heterotypic fibrils.
Hyaline cartilage and endochondral bone formation
Hyaline cartilage, containing type II/XI collagen fibrils, is crucial to
endochondral bone formation during fetal development. In this process, chondrocytes,
the main cellular component of cartilage, first lay down a cartilaginous matrix,
forming a precursor model of the bone. This cartilage model later serves as scaffolding
for osteoblast invasion and calcium deposition during ossification. Apart from its role
in bone formation, non-osteogenic hyaline cartilage can also be found as a structural
component of the larynx, trachea, and the articular surface of bones within joint
capsules.
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Effects of cartilage disorders
Disorders such as mutations in collagen XI genes, affecting the body’s ability
to create or maintain sufficient cartilaginous tissue, can have severe consequences on
human development and health. Without adequate cartilage scaffolding or proper
morphology of the precursor model, bone formation may proceed abnormally,
resulting in shortened or unusually thick bones and appendages2. In cases where the
cartilage is most severely affected, bone and structural development is almost
completely abrogated and death can occur, often due to secondary complications such
as pulmonary hypoplasia9.
Potential for gene therapy for cartilage disorders
The ability to correct such conditions through gene therapy, both in utero and
in children and adults, would be of inestimable benefit. Such treatment could allow
individuals with genetically-based cartilage disorders to receive functional genes that
would produce the necessary products to halt and possibly reverse progression of the
disorder. For such therapies to succeed, however, transgenic constructs must be
created that will function in the correct tissues and provide the needed mitigation of
the targeted disorder.
The chondrodysplasia mouse model
The feasibility of gene therapy for correction of cartilage defects can first be
tested in mouse models of these disorders. One illustrative model of a genetic cartilage
disorder is the murine chondrodysplasia (cho) mutant phenotype. Cho mice possess a
frameshift mutation in the Col11a1 gene, which encodes α1(XI), the α1 chain of the
collagen XI heterotrimer. The mutation introduces a premature stop codon and is
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believed to cause instability of the mRNA transcript, resulting in a functional
knockout of the α1(XI) protein8 (Fig. 1). With no α1 chain to complete the
heterotrimer, type XI collagen is not formed in homozygous mutant fetuses, and the
fetuses exhibit stunted bone development, apparent in their shortened appendages,
poor vertebral and rib development, and micrognathia10. Skeletal staining in these
animals shows that long bones and ribs are not only shortened, but also fail to ossify
correctly, confirming the requirement of collagen XI for proper bone formation (Fig.
2). Mutant fetuses are believed to die at birth from asphyxiation due to pulmonary and
tracheal hypoplasia10. Many structural characteristics of this animal model are similar
to human chondrodysplastic disorders such as Stickler Syndrome, some cases of
which have been linked to COL11A1 mutations11, 12.
Disorders resulting from a null mutation of a collagen gene, such as the
chondrodysplasia of the cho mice, might feasibly be corrected through gene therapy.
Introduction of a functional gene expressing the missing protein under tissue-specific
transcriptional regulation could substitute for the null allele and allow for sufficient
collagen formation, thereby rescuing the mutant phenotype.
COL11A1 transgene development
To test the efficacy of such a treatment we have developed a transgenic
construct, called pCOL11A1, containing a human COL11A1 cDNA under the
transcriptional control of a rat Col2a1 promoter and enhancer in the p1757 expression
vector (Fig. 3). The p1757 vector was kindly provided by Dr. Y Yamada (National
Institute of Dental Research, National Institutes of Health, Bethesda, MD)13. This
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wt CCC CTC GAT AGA AGT GAG AGA TCG ATA GTT
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cho CCC TCG ATA GAA GTG AGA GAT CGA TAG TTG
Figure 1: The cho mutation introduces a premature termination codon. The deletion
of a cytosine ~570 nucleotides downstream of the translation initiation site causes a frame
shift, resulting in a premature stop codon shortly after the mutation site.

+/+

cho/cho

Figure 2: The cho mutation leads to stunted skeletal development. The cho mutant
has a shortened vertebral column, smaller thoracic volume, a shortened lower jaw and
shorter, thicker long bones than wild-type. Red staining (Alizarin red) indicates calcified
bone; blue-green staining indicates uncalcified cartilage (Alcian blue).

Figure 3: Design of the transgenic expression vector for the COL11A1 cDNA.
Details of the design are discussed in Materials and Methods.
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expression vector has been used previously to drive chondrocyte-specific expression
of transgenic constructs14.
The transgenic construct is based on a design from previous unpublished work
in our laboratory15 with modifications made to accommodate a new method of
construction and to potentially enhance expression. This construct will be used in
future studies in the cho mouse model to assess the extent to which the mutant defects
can be corrected through transgenic α1(XI) chain production. We anticipate that the
introduction of a functional COL11A1 transgene into homozygous mutant embryos
will ameliorate the cho phenotype by expressing the missing chain and allowing
skeletal development to proceed normally.
This purpose of this research was to build a COL11A1 transgenic vector
through a relatively new method known as “recombineering” 16. Through this method,
the coding region of a human COL11A1 cDNA was constructed and fused with
necessary regulatory elements before being inserted into the final expression vector. A
vector was also prepared to test the recombinant cDNA through in vitro assays for
expression of the correct protein product.
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Materials and Methods

cDNA GenBank accession numbers
Base pair (bp) identifications for the COL11A1 cDNA refer to GenBank Accession
#NM_001854. This entry describes the COL11A1 mRNA transcript splice variant A,
which includes the alternatively spliced exons 6A, 7, and 8.
Base pair identifications for mouse α-globin gene refer to a portion of the
sequence found under GenBank Accession #NM_039515. This entry describes a large
segment of mouse chromosome 11, part of which contains a complex of globin genes.
The alpha globin gene sequence, comprising bp 29183674-29184493 of this contig, is
numbered herein with the transcriptional start site as bp 1.

Plasmids used
pCR2.1 (Invitrogen): TA cloning vector for ligation and maintenance of Taq
polymerase-amplified PCR product. Contains ampicillin and kanamycin resistance
genes (Amp and Kan, respectively).
pACT2 (Clontech): Plasmid containing the 3’ fragment of human COL11A1 cDNA
(bp 1124-6035) screened from a cDNA library pooled from human knee cartilage15.
Contains Amp.
pBC (Stratagene): Plasmid containing a chloramphenicol resistance gene (CMR); used
as template for amplification of CMR for recombination.
pcDNA3.1 (Invitrogen): In vitro expression vector for transcription/translation assay
of cDNA. Contains Amp and Kan.
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p1757 (Dr. Yoshihiko Yamada, NIH): Transgenic expression vector containing the
Col2a1 promoter, β-globin splice sequence, and Col2a1 enhancer. Contains Amp.

Cloning of 5’ Col11a1 cDNA fragment
Human chondrosarcoma mRNA was kindly provided by Dr. Joel Block (Rush
Medical College). RT-PCR was performed using Qiagen OneStep RT-PCR kit and
primers previously designed15 to amplify the 1506 base pairs of human Col11a1
mRNA beginning at the translation start codon and running to the end of the listed
sequence (bp 319-1824) [Forward sequence: GCGGGATCCATGGAGCCGTGGTCC
TCTAG; Reverse sequence: ATCACCACCATAACGGAACGGTAACATCAACAT
AG]. The primers also introduced a BamHI restriction site at the 5’-most end of the
PCR product. The resulting product was then ligated into pCR2.1 for subsequent
maintenance and use.

Cloning of α-globin gene
PCR was performed on mouse genomic DNA with primers designed to amplify the
last 776 bp of the mouse α-globin gene (GenBank Accession #NT_039515). [Forward
sequence: 5’-CTGGGGAAGACAAAAGCAAC-3’; Reverse sequence: 5’-GCAGGCTTCTTCCT
ACTCAG-3’]

This region of the α-globin gene contains a splice sequence and a

polyadenylation signal, both of which aid in optimal expression of cDNA transgenes17.
The PCR product was then ligated into pCR2.1 for subsequent maintenance and use.
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General recombineering
protocols
Recombinogenic

Gene
name

Product

Function

exo

Exo (RecT
analog)

Digests 5’ ends of PCR
product through
endonuclease activity

bet

Beta (RecE
analog)

Stabilizes single stranded
DNA and facilitates
annealing to complementary
sequence in the cell

gam

Gam

Inhibits endogenous
nuclease activity

engineering, also known as
“recombineering”, is a term
which describes
the process of directed DNA
recombination reactions,
utilizing E. coli bacteria with a
defective λ-prophage stably

Table 1: λ-prophage gene products and functions in
recombineering. Three inducible prophage genes, bet, gam,
and exo, express proteins that aid in recombination.

incorporated into the genome. The prophage genes can be induced through heat shock
to express proteins which aid in the recombination process (Table 1) 16. Samples of
one such strain of E. coli, known as SW10218, were kindly provided by the Dr. Donald
L. Court (National Cancer Institute). The general protocol for initiating recombination
events using this strain was as follows:
Preparation of electrocompetent cells
A liquid culture of SW102 cells in LB broth containing 12.5 µg/ml tetracycline
(SW102 are engineered to be tetracycline-resistant) was incubated overnight at 32°C.
At this temperature, temperature sensitive repressors of the prophage genes are active.
The next day, 1.5 ml of this culture was diluted in 30 ml of LB broth with 12.5 µg/ml
tetracycline and grown at 32°C until OD600~0.5. 20 ml of this culture was cooled
completely on ice and centrifuged at 4000 rpm for 10 minutes at 4°C to pellet cells.
The supernatant was discarded and the cells resuspended in 2ml of ice-cold Nanopure
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water. The resuspended cells were transferred to two cooled 1.5ml eppendorf tubes,
1ml per tube, and centrifuged at ~13500 rpm for 25 seconds at room temperature. The
supernatant was again discarded, and the cells were washed twice more in this manner.
After the final centrifugation, the cells, now electrocompetent, were resuspended in
~50 µl of water and kept on ice until used. ~5-30 ng of plasmid was mixed with the
cells and the cell/plasmid mixture placed in cooled electroporation cuvettes (1 mm).
Plasmid was electroporated into the competent cells (1800 V, 25 µF, 200 Ω), and the
cells were retrieved in 1ml of LB and allowed to incubate for 1 hr at 32°C in a shaking
incubator. Between 50 µl and 150 µl of cells were plated on LB/agar medium
containing the appropriate antibiotic for selection and grown overnight.
Design of PCR primers for recombineering
PCR was performed using Platinum Pfx DNA polymerase kit (Invitrogen) and
specially designed primer sets. Each primer in a set was composed of two fused
elements: 1) a typical 19-to-22-bp primer specific to the PCR template for amplifying
the sequence of interest; and 2) a 50-bp sequence homologous to one of two sequences
on the recombineering target plasmid (on the reverse primer, this sequence was the
reverse complement of the actual target sequence.) On the target plasmid, these
sequences, known as regions of homology (RHs), flanked the spot into which the
amplified sequence was inserted. The product of PCR using such primers contained
the amplified sequence flanked by two 50-base-pair RHs to the recombineering target
plasmid. These regions paired with homologous sequences on the target plasmid
during recombination, allowing for specific, directed recombination to take place.
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Thermal cycler programs for each PCR reaction were created such that the first
five cycles employed a primer annealing temperature approximately 3-5°C below the
melting temperatures of the template-specific segment of the primers (e.g. 52°C for a
primer set with melting temperatures for the template-specific segment of 55°C and
56°C, respectively). This allowed the template-specific region a better opportunity to
bind its target template sequence. The last 30 cycles utilized a primer annealing
temperature of 68°C (the extension temperature for Pfx) with the annealing time
simply added to the extension time at the same temperature (e.g. 1 min 30 sec at 68°C,
instead of a 30-sec step for primer annealing followed by a separate 1 min step for
extension). This allowed for better specificity of the full-length primer when
amplifying template containing both the RHs and the targeted sequence. An example
of a thermal cycler program with these specifications is listed below (Table 2).
Step

Temperature

Time(s)

1. PCR initiation

94°C

2 min

2. Denaturation

94°C

15 sec

3. Primer Annealing #1

52°C

30 sec

4. Extension

68°C (for Pfx)

1 min (for 1 kb product)

5. Go to step 2

N/A

4 times

6. Denaturation

94°C

15 sec

7. Primer Annealing #2 and
Extension

68°C (for Pfx)

1 min 30 sec (for 1 kb
product)

8. Go to step 6

N/A

29 times

Table 2: Sample PCR thermal cycler program for recombineering. The temperature for Step 3
can be adjusted based on the melting temperature of the template-specific primer set. The temperature
for Step 7 should remain 68°C (if using Pfx polymerase) regardless of the primer properties. The
melting temperature for full-length recombineering primers is usually significantly higher than 68°C,
so this temperature will work for any primer set.
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Another element essential to screening for correct recombination is the
presence of a unique antibiotic resistance gene (i.e. one that is not contained in the
target plasmid) in the PCR product along with the sequence of interest. Incorporation
of the resistance gene into the target plasmid through recombination allows for
selection of recombinant colonies with appropriate antibiotic.
PCR product was purified either through electrophoresis and extraction using
QIAEX Gel Extraction Kit (QIAGEN) or with QIAquick PCR Purification Kit
(QIAGEN), both according to supplied protocol.
Recombination into target plasmid
With PCR product in hand, overnight cultures of SW102 colonies containing
the target plasmid were prepared for electroporation as described above, with the
exception of a 42°C incubation for 15 minutes in a shaking water bath prior to cooling
on ice. This incubation induces the expression of recombination proteins encoded by
the prophage genes. Following the final resuspension of cells in ~50 µl of water,
~250-500 ng of purified PCR product was mixed with the cells, and the cell/PCR
product mixture was placed in cooled electroporation cuvettes (1 mm). After
electroporation, ~500 µl of cells were plated on two LB/agar plates with the
appropriate antibiotic selection for overnight growth.
Purification of recombinant plasmid
Colonies resulting from this selection step still contained a mixture of
recombinant and nonrecombinant plasmid, as confirmed by restriction digest. To
further isolate recombinant plasmid, resistant colonies were grown overnight in liquid
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culture, and minipreps were made using QIAGEN Miniprep kit. Isolated plasmid was
diluted to ~0.5 ng/µl, and chemically competent cells were transformed with 1µl of the
dilute plasmid preparation. The majority of the colonies resulting from this
transformation contained only recombinant plasmid, confirmed by restriction digest
and subsequent sequencing.

Primers for COL11A1 trangene recombineering
The following table lists the primer sequences used in recombineering the COL11A1
transgene (Table 3).
Primer
Set
CMR #1

Sequences
Forward – 5’-ATCCCGCTTAACCCGGGAGATCTACGTACGAGCTCGCCGGCGGTCACACTGG
GATTTTGGTCATGAGATTATC-3’ ; Reverse –5’-GCCACCGTTTCGTTTTCCACCTAGAGGAC
CACGGCTCCATGGATCCCGCCGTTTAAGGGCACCAATAACT-3’

CMR/5’

Forward – 5’-GAGATCTGTATGGCTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGGG
GATTTTGGTCATGAGATTATC-3’; Reverse – 5’-GACCAGGTAGACCATCAGCCCCTGGTAA
GCCAGGACGTCCTGGGGGGCCCCTATCGCCAGGGTCACCAG-3’

Kan

Forward – 5’-GAGATCTGTATGGCTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGGG
GCTATCTGGACAAGGGAA-3’; Reverse – 5’-AGCCACCGTTTCGTTTTCCACCTAGAGGACC

CMR #2

Forward – 5’- TGGTGTGGCTAAGATGGAAACAGGGCTGATTCTTGATTCCCAATTCTCAAG
CTCAGTGGAACGAAAACTC-3’ ; Reverse – 5’- AGATGGTGCACGATGCACAGTTGAAGTG

ACGGCTCCATGGATCCCGCTCAGAAGAACTCGTCAAGAAGGC-3’

AACTTGCGGGGTTTTTCAGTATGTAGCAACCAGGCGTTTAAG-3’

cDNA/
CMR

Forward – 5’-GCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCACTAGTAT
GGAGCCGTGGTCCTCTA-3’; Reverse – 5’- GCCCTCTAGACTCGAGCGGCCGCCACTGTGCT

CMR #3

Forward – 5’-GGTCTTTGAATAAAGCCTGAGTAGGAAGAAGCCTGCAAGCCGAATTCTGCG
CTCAGTGGAACGAAAACTC-3’; Reverse – 5’-AGGGCGAATTGGGCCCTCTAGATGCATGCT

GGATATCTGCAGAATTCCGTAGCAACCAGGCGTTTAAG -3’

CGAGCGGCCGCCAGTGTGATGTAGCAACCAGGCGTTTAAG-3’

Alpha/
CMR
cDNA/
alpha/
CMR

Forward – 5’-TGGTGTGGCTAAGATGGAAACAGGGCTGATTCTTGATTCCCAATTCTCAACT
GGGGAAGACAAAAGCAAC-3’; Reverse – 5’-AGATGGTGCACGATGCACAGTTGAAGTGAA
CTTGCGGGGTTTTTCAGTATGTAGCAACCAGGCGTTTAA G-3’

Forward – 5’-CTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCGGAATG
GAGCCGTGGTCCTCTA-3’; Reverse – 5’-CGGAGCCCCATCCACAAAGAGTCAGCCAGCAGC
TCTCACACCCGGCTGGAGTAGCAACCAGGCGTTTAAG-3’

Table 3: Primer sets used in COL11A1 transgene recombineering.
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Results

Specific recombination steps for creation of COL11A1 transgenic vector
The following recombineering steps created the fusion of the COL11A1 cDNA and αglobin gene fragment prior to recombination into the p1757 transgenic expression
vector and pcDNA3.1 in vitro
Plasmid

expression vector (Figs. 4-11). Each step

Forward:
5’-CAGGAAACAGCTATGAC-3’
pCR2.1

was confirmed with restriction digest

Reverse:
5’-GTAAAACGACGGCCAG-3’

and/or cycle sequencing at the BYU

Forward:
5’-TACCCATACGATGTTCCAGATTACGC-3’
pACT2

Sequencing Center using plasmid

Reverse:
5’-GAACTTGCGGGGTTTTTCAGTATCTA-3’

specific primers (Table 4). Final
products were verified through

Primer Set

Forward:
5’-TAATACGACTCACTAT-3’
pcDNA3.1
Reverse:
5’-TAGAAGGCACAGTCGAGGC-3’
Forward:
5’-CCTCTGCTAACCATGTTCAT-3’

restriction digest, PCR with primers for
p1757

Reverse:
5’-GTCTGTCTGATGGAGGGCTG-3’

the full cDNA, and cycle sequencing.
1. Using primer set CMR #1, a
chloramphenicol resistance gene

Table 4: Plasmid-specific
sequencing inserts.

primers

for

(CMR) was amplified from pBC and introduced into pCR2.1 vector containing
the 5’ fragment of the Col11a1 cDNA (TA5’), immediately upstream of the
cDNA insert (Fig. 4).
2. Using primer set CMR/5’, the resulting CMR/5’ cDNA region was amplified
and introduced into pACT2 vector containing the 3’ fragment of the Col11a1
cDNA. The resulting pACT2 plasmid contained CMR immediately followed
by the complete COL11A1 cDNA (Fig. 5).
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3. Using primer set Kan, a kanamycin resistance gene (Kan) was amplified from
pCR2.1, and the CMR upstream of the COL11A1 cDNA was replaced with
Kan (Fig. 6).
The final steps of recombineering followed two different paths. Steps 4a and 5a
created the in vitro expression vector for testing the COL11A1 cDNA for correct
protein expression. Steps 4b through 6b created the final transgenic vector containing
the complete COL11A1 expression cassette for future transgenic experiments.
pcDNA recombineering final steps
4a. Using primer set CMR #2, CMR was amplified from pBC and reintroduced
into pACT2 immediately downstream of the COL11A1 cDNA (Fig. 7).
5a. Using primer set cDNA/CMR, the cDNA/CMR region was amplified and
introduced into pcDNA3.1 within the multiple cloning site, completing the
expression vector for in vitro transcription/translation assays (hereafter called
simply pcDNA) (Fig. 8).
pCOL11A1 recombineering final steps
4b. Using primer set CMR #3, CMR was amplified from pBC and introduced into
pCR2.1 vector containing the α-globin PCR product, immediately downstream
of the insert (Fig. 9).
5b. Using primer set Alpha/CMR, the α-globin/CMR region was amplified and
introduced into the pACT2 plasmid from step 3, immediately downstream of
the cDNA (Fig. 10).
6b. Using primer set cDNA/α-globin/CMR #2, the cDNA/α-globin/CMR region
was amplified and introduced into p1757, immediately following the β-globin
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splice sequence and immediately preceding the Col2a1 enhancer. The
completed vector (herein called pCOL11A1) contains, sequentially, the Col2a1
promoter, a β-globin splice sequence, the COL11A1 cDNA, the α-globin gene
fragment, CMR, and the Col2a1 enhancer (Fig. 11).
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PCR Product

Figure 4: Recombineering step 1. A chloramphenicol resistance gene (CMR) was
inserted immediately upstream of the 5’ fragment of the COL11A1 cDNA in
pCR2.1.
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PCR Product

Figure 5: Recombineering step 2. CMR/5’ cDNA fragment was inserted into
pACT2 containing the 3’ COL11A1 fragment, completing the COL11A1 cDNA
coding sequence.
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PCR Product

Figure 6: Recombineering step 3. CMR was replaced by Kanamycin resistance
gene (Kan) immediately upstream of the COL11A1 cDNA.
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PCR Product

Figure 7: pcDNA recombineering step 4a. CMR was reinserted into the pACT2
plasmid immediately downstream of the COL11A1 cDNA.
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PCR Product

Figure 8: pcDNA recombineering Step 5a. The cDNA/CMR region was inserted
into the pcDNA3.1 in vitro expression vector for testing cDNA protein expression.
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PCR Product

Figure 9: pCOL11A1 recombineering step 4b. CMR was inserted into pCR2.1
immediately downstream of the cloned α-globin fragment.
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PCR Product

Figure 10: pCOL11A1 recombineering step 5b. The α-globin/CMR region was
inserted into pACT2 immediately downstream of the COL11A1 cDNA.
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PCR Product

Figure 11: pCOL11A1 recombineering step 6b. The cDNA/α-globin/CMR region
was inserted into the p1757 transgenic expression vector immediately downstream
of the β-globin splice sequence and immediately upstream of the rat Col2a1
enhancer. This is the completed vector that will be used to create transgenic cho
mice in future studies.
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Sequencing analysis of COL11A1 cDNA
The COL11A1 cDNA used in construction of the transgene vector was sequenced
using a series of primers, most of which were previously designed15 to provide
overlapping results (Table 4). From these results, a definitive determination of the
entire sequence of the recombinant cDNA could be obtained. The results showed
identity with the sequence under GenBank Accession #NM_001854 along the entire
length of the cDNA, except for four single base substitutions (Table 5). These
substitutions should not affect the functioning of the protein as the resulting codons
specify either the same amino acid (in three of the substitutions) or an amino acid with
similar properties (in the remaining substitution).

Digestion analysis of pcDNA and pCOL11A1
Following the final recombineering step, minipreps of pCOL11A1 and the pcDNA
vectors contained a mixture of the final vectors and nonrecombinant p1757 or
pcDNA3.1, respectively. The final vectors have not yet been completely isolated from
nonrecombinant plasmid. Minipreps of the final recombineering mixture were
subjected to restriction digest analysis as a preliminary test for correct recombination.
With proper insertion of cDNA/α-globin/CMR in p1757, digestion with BamHI would
produce two bands of ~275 bp and ~12.6 kb. BamHI digestion of nonrecombinant
p1757 would add a single band at ~5.4 kb. Electrophoresis of this digest showed the
correct series of bands for the recombinant vector, but lacked the correct band for the
non recombinant plasmid. It included instead an additional band of ~7-8 kb (Fig. 12a).
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This unexpected band is as yet unidentified but is probably a recombination product of
p1757.
With the cDNA/CMR insert in the correct location and orientation in
pcDNA3.1, digestion with BamHI would produce one band of ~12.4 kb. BamHI
digestion of nonrecombinant pcDNA3.1 would add a band of ~5.4 kb. Electrophoresis
of this digest showed the correct size of band for the recombinant vector, but lacked
the correct band for the nonrecombinant plasmid. It included instead an additional
band of ~2.0-2.5 kb (Fig. 12b). The smaller band is as yet unidentified.
~12.6 kb
~12.4 kb
~7-8 kb

~2-2.5 kb

(a)

~275 bp

(b)

Figure 12: BamHI restriction digests of pCOL11A1 and
pcDNA. Top and bottom bands in (a) indicate recombinant
vector pCOL11A1. Top band in (b) represents
recombinant vector pcDNA. Addition band in (a) and (b)
are unidentified product.

Sequencing analysis for correct insertion position and orientation
Primers specific to p1757 and pcDNA3.1 (see table 4 above) flanking the
recombineering insertion positions were used to determine proper position and
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orientation of the cDNA insert in pCOL11A1 and pcDNA, respectively. Sequencing
results confirmed the correct insertion position and orientation of each insert.
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Primer name

Sequence

COL11A1 Forward

5’ – ATGGAGCCGTGGTCCTCTA – 3’

COL11A1 Sequencing #2

5’ – AGGGGGACATTCAGCAGTTTTTG – 3’

COL11A1 Sequencing #3

5’ – ATGAAGATAAACCAACAAGCC – 3’

COL11A1 Sequencing #4

5’ – AAAGGACCAACCATCTCTGCTCA – 3’

COL11A1 Sequencing #5

5’ – ACGAGGTTTGCTGGGTCC – 3’

COL11A1 Sequencing #6

5’ – TAAAAGGTGACAGAGGAGAAGTTGGT – 3’

COL11A1 Sequencing #7

5’ – GGATTCCCTGGACCAAAAG – 3’

COL11A1 Sequencing #8

5’ – ACCAGGTCCAGTTGGCTCAC – 3’

COL11A1 Sequencing #9

5’ – CTCCTGGTCCAATAGGTCTTC – 3’

COL11A1 Sequencing #10

5’ – GGTCCTGTTGGTTTTCCTGG – 3’

COL11A1 Sequencing #11

5’ – GAACAAGGGGAAAAAGGTGAC – 3’

COL11A1 Sequencing #12

5’ – AGACCAATCCAGCCCGAACTT – 3’

Table 5: Primers used to sequence the entire COL11A1 cDNA. All primers were designed
previously (Murphy, 2000) except for “COL11A1 Forward”.

Base
number

Base Change

Amino Acid Change

From

To

From

To

462

A

G

Histidine (basic)

Arginine (basic)

3372

G

A

Glycine

Glycine (conserved)

4830

T

C

Glycine

Glycine (conserved)

5088

T

C

Isoleucine

Isoleucine (conserved)

Table 6: Nucleotide changes and resulting amino acids in the reconstructed COL11A1 cDNA.
Only four bases differ from the sequence under GenBank Accession #NM_001854. Three of the four
changes code for the same amino acid as in the listed sequence, while the final change codes for an
amino acid with similar properties.
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Discussion

The COL11A1 transgene vector has now been successfully assembled and, with a few
more steps as discussed below, will be ready for use in the transgenic rescue of the cho
mouse. Prior to using the construct for its designated purpose, however, a few
concerns regarding the design of the transgene should be addressed.

Potential problems with the COL11A1 transgene
Several aspects of the COL11A1 transgene as currently constructed could
potentially limit its effectiveness in a transgenic rescue experiment. Potential
interspecies incompatibility, the utilization of a single COL11A1 splice variant, and
the regulation of COL11A1 by a Col2a1 promoter each raise concerns about the
usefulness of this particular transgene design in rescuing the phenotype of the
homozygous cho mouse.

Problem #1: Will using a human protein in a mouse embryo lead to interspecies
incompatibility?
The COL11A1 cDNA used in construction of the transgene was made from
mRNA extracted from human knee cartilage15. In future experiments the transgene
will be used in cho mouse embryos in an attempt to correct the defects caused by lack
of α1(XI) chain. While human and mouse α1(XI) chains share 91.9% identity of
amino acid sequence, according to NCBI’s HomoloGene, and the same structural
domains are conserved, there is still the possibility that some of the amino acids at the
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points of disparity allow for species-specific functions or interactions. This might limit
the functionality of the transgenically expressed protein in the mouse embryo and
make it difficult to conclusively interpret the results of the transgenic rescue.
However, many of the amino acids that differ between the two analogs are
similar in chemical properties, suggesting that the human and mouse α1(XI) chains
could likely be interchangeable. In addition, the other chains of the human type XI
collagen molecule, α2(XI) and α3(XI), have 93.2% and 95.3% identity, respectively,
with their mouse homologs. The fact that the α1(XI) chain in humans normally
functions with other proteins possessing such high sequence identity with mouse adds
support to the probability that the transgenic α1(XI) protein will also function well in
mice.
Other transgenic mouse rescue experiments using human proteins with lower
amino acid sequence identities have been performed successfully19, 20, 21. Supporting
the feasibility of a collagen rescue with human protein, Col2a1 knockout mice have
been rescued with a human COL2A1 transgene22, indicating that a cross-species rescue
involving collagen is possible. With this encouraging evidence, it appears that a
transgenic rescue using human COL11A1 has a high probability of success.

Problem #2: Will expression of a single COL11A1 mRNA isoform result in
insufficient functionality?
Aside from differences between species, multiple splice variants of the
COL11A1 transcript are expressed even within the same animal. Differential splicing
of COL11A1 occurs in chondrocytes and other tissues in which it is expressed,
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yielding several different isoforms, each coding for a slightly different protein. Exons
6A, 6B, 7 and 8 are variably spliced, with 6A and 6B never occurring in the same
mRNA and exon 7 contained in all variants. Exons 6A and 8 code for acidic peptides,
while 6B codes for a basic peptide. Thus it is evident that the α1(XI) chains resulting
from the different splice variants would have slightly different molecular properties
depending on which exons are included in the final product.
While unique functions have not yet been associated with individual isoforms,
the location of the spliced exons makes it likely that they play an important role. The
variable region of COL11A1 is found within the globular N-terminal domain of the
α1(XI) chain, which resides on the surface of collagen fibrils. In addition to regulating
fibril growth, it has been suggested that this domain might also provide a point of
interaction with surrounding ECM components. If this is true, then it is possible that
different splice variants might fill specific structural niches, interacting with unique
ECM components to maintain a strong, complete and fully functional tissue.
The COL11A1 cDNA used in the transgene codes for the 6A-7-8 splice variant.
This splice variant is one of the most abundantly and widely expressed23 and thus
should be able to function in all COL11A1-expressing tissues. Though the transgenic
animal will not receive the benefit of the full spectrum of isoform expression,
expression of even a single isoform should be sufficient to attenuate the
chondrodysplasia, even if only partially. Should the cartilage in cho/cho mice regain
even a fraction of wildtype functionality, significant and measurable growth beyond
the usual stunted phenotype should be readily observable. Any improvement from the
typical homozygous phenotype would qualify the transgenic rescue as a success.
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Problem #3:Will expressing COL11A1 under Col2a1 regulation lead to type XI
collagen overexpression?
Assuming that the protein for which the transgenic cDNA codes is fully
functional in the mouse embryos, the question still remains: what effect will the
transgenic Col2a1 promoter/enhancer have on the quantity of collagen XI expression?
The typical ratio of type II collagen to type XI collagen in fibrils is approximately 8:1.
When this ratio is increased, in vitro as well as in the cho homozygotes, the fibrils
become shorter, thicker, and spindle-shaped7, 10; when the ratio is significantly
decreased in vitro, the fibrils become longer and thinner than normal. With COL11A1
expressed under the control of the Col2a1 promoter, it is likely that the quantity of
α1(XI) chain will be increased from normal, more closely resembling the expression
of α1(II) chain. With extra α1(XI) chain available, more type XI collagen than normal
could potentially be produced, possibly leading to an in vivo phenotype similar to the
thin, elongated fibrils of the in vitro results mentioned above. The physiological
effects of such altered fibrils in adult cartilage are unknown. Thus overexpression of
type XI collagen as a result of the transgene could be instructive, although
unanticipated.
While some extra type XI collagen could potentially be formed with
overexpression of COL11A1, it seems unlikely that the amount would reach
overwhelming proportions. It should be remembered that the other two chains of the
collagen XI heterotrimer, α2(XI) and α3(XI), would still be expressed at normal
levels. It seems likely that these chains would act to some extent as limiting reagents
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in the formation of collagen XI molecules, although no previous studies have tested
this. The potential fate of the excess α1(XI) chain is uncertain; it might be degraded
soon after translation or perhaps simply accumulate within the endoplasmic reticulum
of the chondrocytes. The collagen fibrils in the extracellular matrix of transgenic
animals, however, would likely remain similar in phenotype to those in wild-type
matrix.
Regardless of the final amount of type XI collagen and its resulting ratio with
type II collagen, a transgenic cho mouse expressing any functional collagen XI will be
an improvement over non-transgenic homozygote expression. Any negative effects
from type XI over-expression would presumably be less severe than the complete lack
of type XI in cho mice. Consequently, even if collagen XI is over-expressed, there
should still be marked improvement in cho skeletal growth and postnatal survival
which would indicate a successful transgenic rescue.
Despite these idiosyncrasies of the transgene construct, all probabilities point
to a successful transgenic rescue. While the final product of the rescue may not mimic
the wild-type phenotype in all aspects, it is anticipated that this construct will provide
for significant improvement in fetal skeletal development and subsequent survival of
transgenic homozygotes after birth. These will be the hallmarks of a successfully
realized transgenic rescue of the cho phenotype.

Future work with the COL11A1 transgene
Construction of the in vitro and transgenic vectors at this point in time is complete.
The recombinant vectors containing the full expression cassettes are still unisolated
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from the nonrecombinant pcDNA3.1 and p1757 vectors. This purification has proven
difficult through the usual method described in “Materials and Methods” above. Two
approaches present themselves as possible methods for isolating the recombinant
plasmids:
1. The vector mixture could be digested with a restriction enzyme which
will only cut once in the final vector, thus linearizing the vector.
Digested vector could be separated on an agarose gel, the correct vector
extracted and purified from contaminants, and recircularized through a
self-ligation reaction. This isolated, religated vector could then be
transformed and amplified for future use. For pcDNA BamHI could be
used for linearization. For pCOL11A1, BamHI could also be used;
however, the digest would remove an ~275 bp fragment from the
internal sequence of the α-globin gene segment. The polyadenylation
signal would be preserved, which is the most important feature of the
α-globin gene segment.
2. The undigested vector mixture could be separated on an agarose gel,
and the correct vector extracted and isolated in circular form. This
extract would be immediately ready for transformation and
amplification in bacteria. This procedure could be complicated should
the recombined and non-recombined plasmid ring exist linked together.
This would require the linearization and electrophoretic separation
described above to isolate the recombinant plasmid. Barring linkage of
the two plasmids, either of these methods should yield purified vector,
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although the second method appears on the surface to be simpler and
more straightforward.
Following isolation, the plasmids should be fully sequenced again to ensure
that no mutations have been introduced through the construction process.
Once isolated and sequenced, these constructs must then be tested for proper
expression prior to their use in transgenic experiments. The pcDNA plasmid
containing the cDNA will be used in in vitro transcription/translation assays to look at
the size and identity of protein coded for by the cDNA. The expressed protein should
be ~181 kD and could be further identified by using α1(XI)-specific antibody.
The pCOL11A1 transgenic vector will also be tested for expression in cultured
chondrocytes before being used to produce transgenic animals. Rat chondrosarcoma
cells will be transfected with the vector and isolated mRNA probed for COL11A1specific sequences. Northern blots should show a band of ~6.4 kb, corresponding to
the fusion mRNA of COL11A1 cDNA and the α-globin fragment, in addition to the
endogenous transcript of ~6 kb or less. Demonstrated expression of this unique mRNA
in chondrocytes, in conjunction with in vitro transcription/translation assays of the
cDNA itself, would confirm that the transgene possesses the ability to express the
expected protein in the desired location. The vector could then be confidently used for
creating transgenic cho animals and evaluating the rescue of the mutant phenotype.
Despite possible difficulties with the COL11A1 transgene as discussed above, a
transgenic rescue of the cho mouse using the pCOL11A1 cassette will be greatly
instructive. Information gleaned from the rescue of this mouse model would provide a
basis for efforts to correct similar human disorders. With the advance of delivery
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methods for therapeutic genetic constructs, an understanding of the principles of gene
therapy for cartilage disorders will pave the way for a cure for many who suffer from
these disorders.

36

Bibliography
1. Liberfarb RM, Levy HP, Rose PS, Wilkin DJ, Davis J, Balog JZ, et al. The Stickler
syndrome: genotype/phenotype correlation in 10 families with Stickler syndrome
resulting from seven mutations in the type II collagen gene locus COL2A1. Genet
Med 2003;5:21-7.
2. Spranger J. The type XI collagenopathies. Pediatr Radiol 1998;28:745-50.
3. Mendler M, Eich-Bender SG, Vaughan L, Winterhalter KH, Bruckner P. Cartilage
contains mixed fibrils of collagen types II, IX, and XI. J Cell Biol
1989;108:191-7.
4. Thom JR, Morris NP. Biosynthesis and proteolytic processing of type XI collagen
in embryonic chick sterna. J Biol Chem 1991;266:7262-9.
5. Keene DR, Oxford JT, Morris NP. Ultrastructural localization of collagen types II,
IX, and XI in the growth plate of human rib and fetal bovine epiphyseal
cartilage: type XI collagen is restricted to thin fibrils. J Histochem Cytochem
1995;43:967-79.
6. Gregory KE, Oxford JT, Chen Y, Gambee JE, Gygi SP, Aebersold R, et al.
Structural organization of distinct domains within the non-collagenous Nterminal region of collagen type XI. J Biol Chem 2000;275:11498-506.
7. Blaschke UK, Eikenberry EF, Hulmes DJ, Galla HJ, Bruckner P. Collagen XI
nucleates self-assembly and limits lateral growth of cartilage fibrils. J Biol
Chem 2000;275:10370-8.
8. Li Y, Lacerda DA, Warman ML, Beier DR, Yoshioka H, Ninomiya Y, et al. A
fibrillar collagen gene, COL11A1, is essential for skeletal morphogenesis. Cell
1995;80:423-30.
9. Hepworth WB, Seegmiller RE, Carey JC. Thoracic volume reduction as a
mechanism for pulmonary hypoplasia in chondrodystrophic mice. Pediatr
Pathol 1990;10:919-29.
10. Seegmiller R, Fraser FC, Sheldon H. A new chondrodystrophic mutant in mice.
Electron microscopy of normal and abnormal chondrogenesis. J Cell Biol
1971;48:580-93.
11. Richards AJ, Yates JR, Williams R, Payne SJ, Pope FM, Scott JD, et al. A family
with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting
in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. Hum Mol
Genet 1996;5:1339-43.

37

12. Brunner HG, van Beersum SE, Warman ML, Olsen BR, Ropers HH, Mariman
EC. A Stickler syndrome gene is linked to chromosome 6 near the COL11A2
gene. Hum Mol Genet 1994;3:1561-4.
13. Yamada Y, Miyashita T, Savagner P, Horton W, Brown KS, Abramczuk J, et al.
Regulation of the collagen II gene in vitro and in transgenic mice. Ann N Y
Acad Sci 1990;580:81-7.
14. Schipani E, Lanske B, Hunzelman J, Luz A, Kovacs CS, Lee K, et al. Targeted
expression of constitutively active receptors for parathyroid hormone and
parathyroid hormone-related peptide delays endochondral bone formation and
rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad
Sci U S A 1997;94:13689-94.
15. Murphy DL. Design and Construction of a COL11A1 Transgene Vector. MS
Thesis. Brigham Young U, 2002.
16. Copeland NG, Jenkins NA, Court DL. Recombineering: a powerful new tool for
mouse functional genomics. Nat Rev Genet 2001;2:769-79.
17. Choi T, Huang M, Gorman C, Jaenisch R. A generic intron increases gene
expression in transgenic mice. Mol Cell Biol 1991;11:3070-4.
18. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and
highly efficient BAC recombineering using galK selection. Nucleic Acids Res
2005;33:e36.
19. Desurmont C, Caillaud JM, Emmanuel F, Benoit P, Fruchart JC, Castro G, et al.
Complete atherosclerosis regression after human ApoE gene transfer in ApoEdeficient/nude mice. Arterioscler Thromb Vasc Biol 2000;20:435-42.
20. Kerr LE, Birse-Archbold JL, Simon A, Logan N, Scott F, Carlson G, et al.
Differential regulation of caspase-3 by pharmacological and developmental
stimuli as demonstrated using humanised caspase-3 mice. Apoptosis
2004;9:739-47.
21. Ke BX, Llanos RM, Wright M, Deal Y, Mercer JF. Alteration of copper
physiology in mice overexpressing the human Menkes protein ATP7A. Am J
Physiol Regul Integr Comp Physiol 2006;290:R1460-7.
22. Rani PU, Stringa E, Dharmavaram R, Chatterjee D, Tuan RS, Khillan JS.
Restoration of normal bone development by human homologue of collagen
type II (COL2A1) gene in Col2a1 null mice. Dev Dyn 1999;214:26-33.
23. Oxford JT, Doege KJ, Morris NP. Alternative exon splicing within the aminoterminal nontriple-helical domain of the rat pro-alpha 1(XI) collagen chain

38

generates multiple forms of the mRNA transcript which exhibit tissuedependent variation. J Biol Chem 1995;270:9478-85.

39

Curriculum Vitae
Cameron McKell Beck
Brigham Young University
Department of Physiology and Developmental Biology
574 Widtsoe Building
Provo, UT 84602
cameronbeck@byu.edu
Education
Brigham Young University
MS, Physiology and Developmental Biology, December 2006
Brigham Young University
BS, Neuroscience, August 2003
Related Experience
Brigham Young University
PDBio 305 Essentials of Human Physiology Lab
Lab Instructor, September 2003-June 2006
Honors and Awards
Graduate Research Mentoring Grant, 2004
Deans List, College of Biology and Agriculture, Fall Semester 2002
Heritage Scholarship, Brigham Young University, 1998-1999

